Results 51 to 60 of about 326,995 (379)

TGF-β-responsive CAR-T cells promote anti-tumor immune function. [PDF]

, 2018
A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-β) enables the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell stimulant.
Chang, ZeNan L, Chen, Yvonne Y, Hou, Andrew J, Lorenzini, Michael H, Zah, Eugenia   +4 more
core   +1 more source

Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy

Frontiers in Immunology
Invariant natural killer T (iNKT) cells are a small subset of T lymphocytes that release large amounts of cytokines such as IFN-γ and exhibit cytotoxic activity upon activation, inducing strong anti-tumor effects.
Mariko Takami, Shinichiro Motohashi
doaj   +1 more source

The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors

Frontiers in Immunology, 2017
Research on adult cancer immunotherapy is proceeding at a rapid pace resulting in an impressive success rate exemplified by a few high profile cases. However, this momentum is not readily extended to pediatric immunotherapy, and it is not for lack of ...
Thanh-Phuong Le, To-Ha Thai
doaj   +1 more source

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. [PDF]

, 2014
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages.
Albelda, Steven M., Antzis, Michael, Cotner, Cody E., Durham, Amy C., Johnson, Laura A., June, Carl H., Kapoor, Veena, Lo, Albert, Majumdar, Rajrupa S., Puré, Ellen, Scholler, John, Solomides, MD, Charalambos C., Sun, Jing, Wang, Liang-Chuan S.   +13 more
core   +2 more sources

Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors

Hematology, Transfusion and Cell Therapy, 2021
The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors.
Mirella Nardo, Tatiane C. Motta, Leandro M. Colli, Mauro P. Avanzi   +3 more
doaj  

Memory NK cell features exploitable in anticancer immunotherapy [PDF]

, 2019
Besides their innate ability to rapidly produce effector cytokines and kill virus-infected or transformed cells, natural killer (NK) cells display a strong capability to adapt to environmental modifications and to differentiate into long-lived ...
Battella, Simone, Capuano, Cristina, Galandrini, Ricciarda, Palmieri, Gabriella, Pighi, Chiara, Santoni, Angela   +5 more
core   +2 more sources

Chimeric Antigen Receptor T Cell Therapy in Hematology

Turkish Journal of Hematology, 2015
It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell ...
Pınar Ataca, Önder Arslan
doaj   +1 more source

Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects

Vaccines, 2022
Neoantigens are abnormal proteins produced by genetic mutations in somatic cells. Because tumour neoantigens are expressed only in tumour cells and have immunogenicity, they may represent specific targets for precision immunotherapy.
Lei Gao, Anqi Zhang, Fuyuan Yang, Wei Du
doaj   +1 more source

Biomaterial-based ligand presentation to induce notch signaling in vitro [PDF]

, 2013
T cell adoptive transfer is an important procedure in immunotherapy. In immunocompromised patients, T cells may need to be developed from stem cells, requiring the induction of Notch signaling events responsible for native T cell differentiation in the ...
Mehta, Naveen
core   +1 more source

Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.

Cancer Research, 2018
Medulloblastoma is the most frequent malignant childhood brain tumor with a high morbidity. Identification of new therapeutic targets would be instrumental in improving patient outcomes.
D. Orlando, E. Miele, B. De Angelis, M. Guercio, I. Boffa, M. Sinibaldi, A. Pò, Ignazio Caruana, L. Abballe, A. Carai, S. Caruso, A. Camera, A. Moseley, R. Hagedoorn, M. Heemskerk, F. Giangaspero, A. Mastronuzzi, E. Ferretti, F. Locatelli, C. Quintarelli   +19 more
semanticscholar   +1 more source